Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01625936
Title CRLX101 Plus Bevacizumab in Advanced RCC
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

renal cell carcinoma

Therapies

Bevacizumab

NLG207

Age Groups: adult
Covered Countries USA


No variant requirements are available.